Evaluation of Selected Cytokine Gene Expression in Colonic Mucosa from Dogs          with Idiopathic Lymphocytic-plasmacytic Colitis

Tamura, Yu; Ohta, Hiroshi; Yokoyama, Nozomu; Lim, Sue Yee; Osuga, Tatsuyuki; Morishita, Kayoko; Nakamura, Kensuke; Yamasaki, Masahiro; Takiguchi, Mitsuyoshi

doi:10.1292/jvms.13-0635

Cited by 25 publications

(29 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have investigated cytokine profiles in the duodenal and colonic mucosa of dogs with IBD at mRNA or protein levels, but consistent results have not yet been obtained . A previous study reported absolute and relative increases in IL‐1β in the duodenal mucosa of dogs with IBD .…”

Section: Discussionmentioning

confidence: 98%

“…All dogs showed both small and large bowel diarrhea with or without vomiting. The median CCECAI score was 7 (range, [3][4][5][6][7][8][9][10][11][12][13][14]. The median WSAVA scores in the duodenum and in the colon were 10.5 (range, 6-17) and 4 (range, 2-9), respectively.…”

Section: Clinical and Histopathological Characteristics Of Dogs Witmentioning

confidence: 99%

“…Previous studies reported no significant difference in mRNA expression of IL-1b in the colonic mucosa between dogs with IBD and healthy dogs. 6,7 However, expression and balance of IL-1b and IL-1Ra proteins have not been investigated previously in the colonic mucosa of dogs with IBD.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of interleukin‐1β on occludin mRNA expression in the duodenal and colonic mucosa of dogs with inflammatory bowel disease

Ogawa

Osada

Hasegawa

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundMucosal imbalance of interleukin (IL)‐1β and IL‐1 receptor antagonist (Ra) has been reported in the duodenal mucosa of dogs with inflammatory bowel disease (IBD). However, the imbalance in the colonic mucosa and its role in duodenitis and colitis in IBD of dogs remain unclear.ObjectivesTo measure the expression of IL‐1β and IL‐1Ra proteins in the colonic mucosa of dogs with IBD, and to determine the effect of IL‐1β on expression of occludin (ocln) mRNA, a tight junction component, in the duodenal and colonic mucosa of dogs with IBD.AnimalsTwelve dogs with IBD and 6 healthy dogs.MethodsIL‐1β and IL‐1 Ra proteins in the colonic mucosa were quantified by ELISA in 7 of the 12 dogs with IBD. Expression of ocln mRNA in the duodenal and colonic mucosa was examined in the 12 dogs by real‐time PCR.ResultsThe ratio of IL‐1β to IL‐1Ra in the colonic mucosa was significantly higher in dogs with IBD than in healthy dogs. The ex vivo experiment determined that IL‐1β suppressed expression of ocln mRNA in the colonic mucosa, but not in the duodenal mucosa, of healthy dogs. Expression of ocln mRNA in the colonic mucosa, but not in the duodenal mucosa, was significantly lower in dogs with IBD than in healthy dogs.Conclusions and Clinical ImportanceA relative increase in IL‐1β may attenuate ocln expression, leading to intestinal barrier dysfunction and promotion of intestinal inflammation in the colonic mucosa, but not in the duodenal mucosa, of dogs with IBD.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Clinical and Histopathological Characteristics Of Dogs Witmentioning

confidence: 99%

See 1 more Smart Citation

Effect of interleukin‐1β on occludin mRNA expression in the duodenal and colonic mucosa of dogs with inflammatory bowel disease

Ogawa

Osada

Hasegawa

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Several reports describe various components of the cytokine signature (interleukin [IL]‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8, IL‐10, IL‐12p40, IL‐17, IL‐18, IL‐23, IL‐25, IL‐33, IFN‐γ, TNF‐α, and TGF‐β1) in dogs with CIE,137, 138, 139, 140, 141, 142, 143 all of which do not support a Th1 nor Th2 polarization as described for inflammatory bowel diseases in humans 144, 145. There also is no evidence of a Th17 signature in dogs with CIE 146, 147.…”

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

“…135 The lack of a correlation between serum sRAGE and S100A12 concentrations suggests that sRAGE is a nonspecific decoy receptor in dogs. 27 Similar to inflammatory bowel disease in humans, 136 [IL]-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p40, IL-17, IL-18, IL-23, IL-25, IL-33, IFN-γ, TNF-α, and TGF-β1) in dogs with CIE, [137][138][139][140][141][142][143] all of which do not support a Th1 nor Th2 polarization as described for inflammatory bowel diseases in humans. 144,145 There also is no evidence of a Th17 signature in dogs with CIE. 146,147 One problem with using cytokines as biomarkers in dogs is that there are many cytokine assays available.…”

Section: Soluble Receptor For Advanced Glycation End Productsmentioning

confidence: 99%

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Heilmann

Steiner

2018

Veterinary Internal Medicne

108

View full text Add to dashboard Cite

Chronic inflammatory enteropathies (CIE) in dogs are a group of disorders that are characterized by chronic persistent or recurrent signs of gastrointestinal disease and histologic evidence of mucosal inflammation. These CIEs are classified as either food‐responsive, antibiotic‐responsive, or immunosuppressant‐responsive enteropathy. Patients not clinically responding to immunomodulatory treatment are grouped as nonresponsive enteropathy and dogs with intestinal protein loss as protein‐losing enteropathy. Disease‐independent clinical scoring systems were established in dogs for assessment of clinical disease severity and patient monitoring during treatment. Histopathologic and routine clinicopathologic findings are usually not able to distinguish the subgroups of CIE. Treatment trials are often lengthy and further diagnostic tests are usually at least minimally invasive. Biomarkers that can aid in defining the presence of disease, site of origin, severity of the disease process, response to treatment, or a combination of these would be clinically useful in dogs with CIE. This article summarizes the following biomarkers that have been evaluated in dogs with CIE during the last decade, and critically evaluates their potential clinical utility in dogs with CIE: functional biomarkers (cobalamin, methylmalonic acid, folate, α1‐proteinase inhibitor, immunoglobulin A), biochemical biomarkers (C‐reactive protein, perinuclear anti‐neutrophilic cytoplasmic antibodies, 3‐bromotyrosine, N‐methylhistamine, calprotectin, S100A12, soluble receptor of advanced glycation end products, cytokines and chemokines, alkaline phosphatase), microbiomic biomarkers (microbiome changes, dysbiosis index), metabolomic biomarkers (serum metabolome), genetic biomarkers (genomic markers, gene expression changes), and cellular biomarkers (regulatory T cells). In addition, important performance criteria of diagnostic tests are briefly reviewed.

show abstract

Inflammatory Bowel Disease in Humans, Pets, and Horses

Roth‐Walter

Berger

Luckschander-Zeller

2017

Comparative Medicine

View full text Add to dashboard Cite

Evaluation of Selected Cytokine Gene Expression in Colonic Mucosa from Dogs with Idiopathic Lymphocytic-plasmacytic Colitis

Cited by 25 publications

References 15 publications

Effect of interleukin‐1β on occludin mRNA expression in the duodenal and colonic mucosa of dogs with inflammatory bowel disease

Effect of interleukin‐1β on occludin mRNA expression in the duodenal and colonic mucosa of dogs with inflammatory bowel disease

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Inflammatory Bowel Disease in Humans, Pets, and Horses

Contact Info

Product

Resources

About